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Abstract
The evolution of drug resistant Plasmodium parasites is a major challenge to effective malaria control. In theory, competitive
interactions between sensitive parasites and resistant parasites within infections are a major determinant of the rate at
which parasite evolution undermines drug efficacy. Competitive suppression of resistant parasites in untreated hosts slows
the spread of resistance; competitive release following treatment enhances it. Here we report that for the murine model
Plasmodium chabaudi, co-infection with drug-sensitive parasites can prevent the transmission of initially rare resistant
parasites to mosquitoes. Removal of drug-sensitive parasites following chemotherapy enabled resistant parasites to
transmit to mosquitoes as successfully as sensitive parasites in the absence of treatment. We also show that the genetic
composition of gametocyte populations in host venous blood accurately reflects the genetic composition of gametocytes
taken up by mosquitoes. Our data demonstrate that, at least for this mouse model, aggressive chemotherapy leads to very
effective transmission of highly resistant parasites that are present in an infection, the very parasites which undermine the
long term efficacy of front-line drugs.
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Introduction
Global deployment of antimalarial drugs in the latter half of the
20
th century placed enormous selection pressure on human
malaria parasites to evolve resistance. In many parts of the world,
front-line drugs such as chloroquine and sulphadoxine-pyrimeth-
amine (SP) are now ineffective against Plasmodium falciparum, and
the available alternatives are increasingly threatened [1–3].
Indeed, the World Health Organization [4] considers the
evolution of drug resistance by malaria parasites to be inevitable,
and acknowledges that for as long as malaria is around, a drug-
discovery pipeline will be required to replace drugs as they fail [5].
The speed of this ‘drug treadmill’ is determined primarily by the
rate at which mutations conferring resistance arise and reach
transmissible densities in an infection, and by the rate at which
they spread in a population [6].
It has become apparent that malarial infections typically
comprise multiple parasite genotypes, particularly in areas of high
transmission (e.g. [7–18]). Within mixed infections, powerful
genotype-genotype crowding effects can occur, as shown both by
correlational epidemiologic evidence for human infections [9,19–
25] and by direct experimental investigation using the rodent
malaria Plasmodium chabaudi in laboratory mice [26–35]. Compe-
tition among clones can be a major brake on the rate of resistance
evolution because the onward transmission of resistant parasites
acquired by either transmission or by de novo mutation can be
stifled by competitors in the absence of drug treatment.
Conversely, removal of drug-sensitive competitors by chemother-
apy can greatly enhance the spread of parasites with high-level
resistance. Thus, clone interactions in the presence and absence of
drug treatment are major determinants of the useful lifespan of a
drug [6,36–42].
The development of evidence-based resistance management
strategies requires an understanding of these clone-clone interac-
tions within hosts [42]. Some analysis in human Plasmodium
infections is possible [25,43], but direct experimental investigations
require that chemotherapy be denied to some individuals with
malaria. Consequently, experimental work has focused on rodent
models. There, competitive release has been demonstrated for
resistant P. chabaudi parasites after prophylactic [28] and thera-
peutic [33–35] drug treatment. Competitive release can even lead
to facilitation, where resistant parasites attain higher densities
following the clearance of susceptible competitors than they would
have achieved in single clone infections [33].
These rodent malaria studies have assumed that relative and
absolute fitness (transmission success) of resistant parasites can be
inferred from their density in gametocyte populations in peripheral
blood sampled from the mouse tail vein. Transmission of human
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density within the host [44–46], and Hill et al. [47] observed that
the extent of parasite multiplicity in infected people was reflected
in the parasite diversity in Anopheles mosquitoes. A limited body of
empirical evidence for P. chabaudi (e.g. [27,28,48]) and the lizard
malaria, P. mexicanum [49], shows that gametocyte densities of co-
infecting parasites in host blood correlate with transmission success
of individual clones to mosquitoes (or sandflies in the lizard-
malaria model). Here we determine whether this assumption holds
true following chemotherapy. Clones of P. falciparum that survive
drug treatment produce infectious gametocytes [13], but relative
infectivity of resistant and sensitive parasites remains to be
demonstrated. In P. chabaudi, drug treatment and competition
independently affect determinants of infectivity (e.g. [50–53]) and
there are situations where the clonal composition of parasite
populations in mice is not well correlated with the genetic
composition of parasites in mosquitoes fed on those hosts (e.g.
[54]). Some authors have also suggested that variation in parasite
transmission among mosquitoes fed on the same host at the same
time might be in part due to aggregation of gametocytes in skin
capillaries prior to ingestion by the mosquitoes [55,56]. If so, the
actual uptake of gametocytes from host capillaries by mosquitoes
might differ from the gametocyte densities identified in tail-snip
venous blood samples, particularly at low gametocyte densities.
Here we test whether transmission consequences of drug
treatment as inferred from gametocyte densities do in fact play
out in transmission in a P. chabaudi – An. stephensi model system. We
deliberately initiated infections with a highly skewed ratio of
sensitive to resistant parasites because we knew from previous
work [57] that drug treatment would lead to substantial changes in
clone frequencies. We determined the densities of resistant and
sensitive parasites in the presence and absence of drug treatment at
two life stages in both hosts: in the asexual and gametocyte
populations in the mouse, and in the blood meal and oocysts in the
mosquito. Parasite dynamics of mixed-clone infections in the




The study was carried out in strict accordance with the
recommendations in the guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. The protocol was
approved by the Animal Care and Use Committee of the
Pennsylvania State University (Permit Number: 35790).
Parasites and Hosts
Two genetically distinct clones were used in the experiment:
The pyrimethamine-sensitive clone AJ5P (hereafter referred to as
clone S) and the pyrimethamine-resistant clone AS6P(pyr-1A)
(hereafter referred to as clone R). Both clones were isolated from
individual thicket rats and subsequently cloned as detailed by
Beale et al. [58]. Clone R was made resistant by a single high-dose
exposure to pyrimethamine [59].
Experimental murine hosts were 8 week old female C57Bl/6
laboratory mice (Charles River Laboratories). All mice were
maintained at 26uC with a 12L:12D photoperiod, fed Laboratory
Rodent Diet 5001 (LabDiet, PMI Nutrition International) and
received drinking water supplemented with 0.05% para-amino
benzoic acid to enhance parasite growth [60].
Experimental Design, Drug Treatment and Mosquito
Feeds
Twenty mice were each challenged with mixed infections of
clone R (10
2 parasites) and clone S (10
6 parasites). We used these
very unequal inocula to establish infections initially dominated by
sensitive parasites; previous work [31,57] had demonstrated that
these starting conditions generate substantial competitive suppres-
sion of resistant parasites in the absence of chemotherapy, and
substantial competitive release following drug treatment [31,33–
35]. Resistant parasites will often be rare in untreated infections in
nature when, for instance, there is a competitive disadvantage
associated with the costs of resistance [31,33,34,40] or when
resistance first arises de novo.
Inoculations were prepared from donor mice by diluting blood
in 0.1 ml of calf serum solution (50% heat-inactivated calf serum,
50% Ringer’s solution [27 mM KCl, 27 mM CaCl2, and
150 mM NaCl] and 20 units of heparin per millilitre) and were
introduced by intra-peritoneal (i.p.) injection. Ten mice were drug
treated and ten were sham treated. Drug treatment was initiated
on day six post-infection (PI), the time point at which pronounced
anaemia and weight loss become apparent (see [33,34]). Treat-
ment consisted of 8 mg/kg pyrimethamine dissolved in dimethyl
sulfoxide (DMSO), administered as a 50 ml i.p. injection on four
successive days. Sham-treated mice received contemporaneous i.p.
injections of 50 ml of DMSO without pyrimethamine.
To measure the transmission effects of treatment, Anopheles
stephensi mosquitoes were allowed to feed on experimental mice
over a week, starting two days after drug treatment finished. For
the transmission experiments, twelve of the twenty mice were
chosen at random among survivors (see results), six of whom had
been drug-treated. In this feeding experiment, each mouse was
used every second day, with half the mice allocated to even days
(days 12, 14, 16, 18 PI) and half to the alternate days (13, 15, 17,
19 PI) cross-factored with drug treatment in a fully balanced
experimental design. Thus, each mouse was offered to mosquitoes
on four separate occasions over 8 days.
Approximately thirty mosquitoes (2–5 days old) were introduced
into individual half-liter plastic cups via a slit in the mesh-covered
top. The cups had roughened internal surfaces to facilitate
mosquito resting and the mesh slit was plugged with cotton wool
to prevent escape. An additional pad of cotton wool soaked in 5%
glucose solution was placed on the surface of each cup’s mesh
cover to enable feeding ad. lib. and the cups were kept in the
incubator along with stock cages. Incubator conditions of 26uC,
70% relative humidity and a 12L:12D photoperiod were
maintained throughout the course of the experiment. Glucose
pads were removed from cups one hour before experimental blood
feeds. Mice were anaesthetised immediately prior to blood feeds
with a 0.05 ml i.p. injection of Ketamine (100 mg/kg)/Xylazine
(10 mg/kg). Once unconscious, individual mice were laid upon the
mesh covering of each cup and the mosquitoes allowed to blood
feed for 30 minutes. Mice were then returned to their cages to
recuperate, unfed mosquitoes were removed from cups and new
glucose pads provided.
Monitoring Infection Dynamics in Mice
Mice were sampled before noon on a daily basis between days
five and 19 PI. A thin blood smear was made, morbidity
monitored by recording mouse body mass (to the nearest 0.01 g)
and 2 ml of blood taken via a tail snip to determine red blood cell
(RBC) density using flow cytometry (Beckham Coulter). Additional
5 ml and 10 ml blood samples were collected for DNA and RNA
extraction, respectively. Blood samples for DNA extraction were
handled and extracted as detailed by Bell et al. [32]. Blood samples
Malaria Transmission following Drug Treatment
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phosphate buffered saline (PBS: Ca
2+/Mg
2+ -free) and 20 ml
Nucleic Acid Purification Lysis Solution (Applied Biosystems), the
mixture immediately vortexed to allow complete lysis and the
lysate kept on ice prior to storage at 280uC. Total RNA was
extracted using the ‘‘RNA Blood-DNA’’ method, on the ABI
Prism 6100 Nucleic Acid Prepstation, with an elution volume of
100 ml. RNA was immediately converted to cDNA using the High-
Capacity cDNA Archive Kit (Applied Biosystems). Both RNA and
cDNA were stored at 280uC.
Parasite densities were determined using clone-specific PCR
primers and minor groove-binder (MGB) probes, targeting either
the P. chabaudi ama gene (for quantification of total parasite
densities [considered to equate to asexual parasite densities] from
DNA [32]) or the common gametocyte gene (CG1, for quantification
of gametocytes from cDNA; as [61]). Real-time quantitative PCRs
were performed on an ABI Prism 7500 Fast System with an initial
denaturation of 95uC for 2 min followed by 40 cycles of
denaturation at 95uC for 3 sec and annealing/extension at 60uC
for 30 sec. For the ama assay, 2 ml of DNA were included in a total
PCR reaction volume of 25 ml with 16PerfeCTa
TM qPCR
FastMix
TM (Quanta Biosciences), forward and reverse primers at
300 nM and TaqManH MGB probe (Applied Biosystems) at
200 nM. The CG1 cDNA assay incorporated 7 ml of cDNA (at a
1:10 dilution) in a total reaction volume of 25 ml with
16PerfeCTa
TM qPCR FastMix
TM (Quanta Biosciences), forward
and reverse primers at 900 nM and TaqManH MGB probe
(Applied Biosystems) at 250 nM. Absolute quantification was
based on a standard curve of serial dilutions of DNA and cDNA
standards of known asexual parasite and gametocyte densities,
respectively, determined beforehand by careful microscopy
(validated by [32,33,61–64]).
Monitoring Transmission to Mosquitoes
Immediately post-blood feed, two fully engorged mosquitoes
were removed from each pot, anaesthetised with chloroform and
placed individually into 1.5 ml microfuge tubes containing 500 ml
of RNAlater
TM (Qiagen), with care taken to ensure that
mosquitoes were totally submerged. Tubes were stored at
280uC until RNA extraction. Mechanical disruption of mosqui-
toes was achieved with a TissueLyser (Qiagen) under the following
conditions. Upon thawing, mosquitoes were removed from the
RNAlater
TM and placed individually into collection microtubes
containing 600 ml of Buffer RLT from the RNeasy
TM Protect Mini
Kit (Qiagen), 0.25 g of sterile 0.2 mm zirconium beads (OPS
Diagnostics, LLC) and 0.25 g of sterile 0.8 mm silica beads (OPS
Diagnostics, LLC). Mosquitoes were then ground for 2 mins at 30
Hertz, with the microtubes repositioned within the TissueLyser
every 30 s to ensure uniformity of disruption for all samples. RNA
was then extracted using the RNeasy
TM Protect Mini Kit (Qiagen)
according to the manufacturer’s instructions and eluted in a
volume of 100 ml. The RNA was handled and stored as detailed
above for that obtained from mouse blood samples. Gametocyte
densities present within mosquito blood-meals were quantified as
described for mouse blood-derived cDNA.
Mosquitoes not sub-sampled for blood-meal analysis were kept
within the incubator and fed glucose ad lib. until dissection at 9
days post-blood feed. Mid-guts were examined for intensity of
infection (number of oocysts) using a compound microscope and
infected guts placed individually into 30 ml of chilled PBS within
1.5 ml microtubes. Tubes were maintained on ice prior to storage
at 280uC. DNA was extracted from individual mosquito mid-guts
using the E.Z.N.A MicroElute Genomic DNA kit (Omega Bio-
Tek) as per manufacturer’s instructions, eluted in a total volume of
20 ml and stored at 280uC. Clone densities present within oocysts
on mid-guts were determined as for DNA samples obtained from
mouse blood samples.
Statistical Analyses
To summarize asexual and gametocyte parasite densities
through time, the geometric mean densities were calculated for
clone R, clone S or both (total densities) for each mouse for the
entire infection course (d5 – d19 PI) and for feed days (either days
12, 14, 16, 18 or days 13, 15, 17 and 19 PI, dependent upon
mouse). General linear modeling (MINITAB v. 14) was used to
compare the effect of drugs (treated or untreated) on parasite
densities. The relationship between gametocyte density and the
probability of mosquito infectivity for the two clones was studied
using logistic regression. Logistic regression was performed in the
statistical software environment R (version 2.11.1 [65]), using a
generalized linear model with a binomial distribution and logit link
function. The predicted infectivity and 90% prediction interval
(i.e., 90% probability that future observations will fall within these
bounds) were estimated from the fit model. Since regression
parameters (a and b) were estimated on the logit scale, predicted
values were obtained using the logit transformation
q~ eazbN
1zeazbN ð1Þ
where a and b are parameters from the linear regression p=ax+b
on the logit scale.
Results
Mouse Morbidity
Four sham-treated mice had to be euthanized before the
commencement of mosquito feeds in accordance with animal care
guidelines. All drug-treated mice (n=10) remained outwardly
healthy with significantly less weight loss (total weight loss:
F1,15=57.4, p,0.001) and anaemia (minimum RBC density:
F1,15=53.4, p,0.001) than non-drug treated mice (n=6) during
the monitoring period (days 5–19 PI).
Parasite Performance Prior to Drug Treatment
Before drug treatment began on day 6 PI, there were no
significant differences in parasite densities within hosts of each
treatment group (Figures 1 and 2; resistant asexuals: F1,19=1.1,
p=0.31; resistant gametocytes: F1,19=0.7, p=0.42; susceptible
asexuals: F1,19=2.6, p=0.13; susceptible gametocytes:
F1,19=0.03, p=0.86). The 10,000-fold difference in the densities
of sensitive and resistant parasites we created at the beginning was
maintained through to the start of drug treatment at day 6 p.i.
(Figure 1– both panels; Figure 2), at which point there were only
179.5 (626.8 [s.e.m]) resistant asexual parasites and 3.6 (61.02)
resistant gametocytes per microliter of mouse blood.
Fate of Resistant Parasites in Treated and Untreated Mice
In the absence of drug treatment, the infection was dominated
by the susceptible parasites (Figure 1– top panel; Figure 2– panels
A–F). Indeed, in four of six untreated mice, resistant asexual
parasites were excluded from the infection (below stochastic
detection levels) by day 10 PI. Gametocytes from the resistant
clone were detected on only two days at most in untreated mice,
and never after day 7 PI. Thus, in the absence of drug treatment,
the resistant clone had negligible transmission potential.
At the start of drug treatment, resistant parasites constituted less
than 0.05% of the parasite and gametocyte populations. After
Malaria Transmission following Drug Treatment
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(Figure 1– bottom panel, Figure 2– panels G–L), so that the
resistant clone became the numerically dominant two days after
the cessation of drug treatment (day 11 PI). A day later, the
resistant clone made up more than 95% of the parasite population
(Figure 3). Drug treatment completely cleared susceptible parasites
in only two of the six mice used for mosquito blood feeds (Figure 2–
panels I & L). In the other four mice, susceptible parasites were
undetectable for 2 to 8 days before they recrudesced to varying
degrees (Figure 2– panels G, H, J & K).
Total Parasite Burdens
In the absence of drug treatment, parasite populations were
almost exclusively clone S, whereas drug-treated populations were
dominated by the resistant clone (Figures 1 and 2). For mice used
in the mosquito feeds, drug treatment reduced total asexual
parasites densities across the monitoring period (sum of R & S
clones; geometric means across day 5–19 PI; F1,11=38.4,
P,0.001).
Total gametocyte densities were unaffected by drug treatment
(F1,11=0.58, P=0.46): drug treatment simply replaced drug-
sensitive gametocytes with drug-resistant gametocytes (Figures 1
and 2).
Figure 1. Densities of asexual parasites (solid lines) and gametocytes (dotted lines) of drug-sensitive (clone S, black) and drug-
resistant (clone R, gray) parasites within sham-treated (top panel) and drug-treated (bottom panel) mice. Dashed and shaded boxes
show days of sham or drug treatment. Data are log-transformed geometric means (6 S.E) of a maximum of 10 mice (number of untreated mice [top
panel] reduced to six by day 12 due to morbidity-driven euthanasia).
doi:10.1371/journal.pone.0037172.g001
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e37172Figure 2. Asexual and gametocyte densities of clone S and clone R within the 12 randomly selected mice used for mosquito blood
feeds (see methods), gametocyte densities within blood-meals (denoted by crosses), prevalence of mosquito infection (percentage
and numbers of infected mosquitoes at each feed) and identity of oocysts present on mid-guts 9 days post-blood feed (S: clone S
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Gametocyte densities in mosquito blood-meals over time, and
the prevalence of infection in mosquitoes(% with oocysts on the
midgut) are shown in Figure 2. Direct quantitative comparisons
between gametocytes present in a micro-liter of mouse blood and
within a mosquito blood-meal taken from that mouse must take
into consideration that different RNA extraction protocols were
employed for each. Indeed, gametocytes were typically not
quantifiable within the blood-meal when the gametocyte density
in mouse blood was less than about 30 gametocytes/ml (Figure 2–
panels C, E–L).
In the absence of drug treatment, no clone R gametocytes were
detectable in mouse blood at the time of mosquito feeds and so,
unsurprisingly, no resistant gametocytes were identified in
mosquito blood-meals (Figures 3A & 3B) and none of the oocysts
which subsequently developed contained resistant parasites
(Figure 2– panels A, B, C, D, E, F). Drug treatment reversed
this, with resistant parasites dominating in treated mice at the time
of mosquito blood feeds (98.8%), in the blood meals of mosquitoes
feeding on those mice (98.0%), and in the oocysts which
subsequently developed (98.6% of 139 oocysts, 99.6% of the
genomes [= sporozoites]) (Figures 3A, 3B & 2– panels G, H, I, J,
K, L).
Drug treatment did not have an impact on infectiousness of the
mice (Fig 3C; F1,11=2.1, p=0.18), with similar proportions of
mosquitoes becoming infected from non-drug-treated (19.4%, 6
S.E: 4.4; range of 5.3 to 32.3%) and drug-treated mice (12%, 6
S.E: 2.6; range of 5.8 to 20%).
genotype; R: clone R genotype; R+S: both clone genotypes). Panels A-F, non-drug-treated mice (D2); panels G–L, drug-treated mice (D+); nf:
no blood feed performed due to mouse morbidity. Dotted and grey blocks show period of sham or drug treatment.
doi:10.1371/journal.pone.0037172.g002
Figure 3. Transmission parameters. A. Frequency of gametocytes of the resistant clone present in the blood of sham-treated (diamonds) and
drug-treated (squares) mice used for mosquito blood feeds. Shaded area indicates timing of treatment. Each data point represents the mean (61
S.E.M) from six mice. B. Percentage of clone R gametocytes in mouse blood at time of mosquito blood feeds (dark bars) and in mosquito blood-meals
fed on those mice (gray bars), for non-drug-treated and drug-treated mice. There were no gametocytes from the resistant clone in untreated mice. C.
Prevalence of infection with each clone in mosquitoes fed on each of the six treated and six sham-treated mice. Plotted points are the mean (6 SEM)
for each mouse across all four feed days, with c.30 mosquitoes per feed. Diamonds, S alleles; squares, R alleles. (2 of 83 infections corresponding to
either S or S+R alleles are not included).
doi:10.1371/journal.pone.0037172.g003
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Blood and Prevalence of Infection in Mosquitoes
The densities of R gametocytes in mouse blood on feed days
and in the blood-meals of mosquitoes that fed on that mouse were
highly correlated across more than 4 orders of magnitude, with a
regression slope nearing 1 and an intercept not distinguishable
from zero (Figure 4; F=109.1, p,0.001, slope=0.90260.09,
intercept=0.1660.26). This means that any clumping of game-
tocytes in host capillary beds [55,56] is not affecting the efficiency
of transmission of gametocytes to mosquitoes.
In the absence of drug treatment, only clone S was transmitted
to mosquitoes. Successful formation of oocysts was observed only
when gametocyte densities exceeded 10
2.5/ml of mouse blood
(Figure 5). Prevalence of infection rose sharply with increasing
gametocyte densities, withevery mouse exceeding this threshold
infectious to mosquitoes. Following drug treatment, successful
transmission was almostentirely due to resistant parasites, although
one mosquito harboured a single oocyst with just the clone S
genotype (Figure 2– panel G) and another mosquito bore an
oocyst that had apparently resulted from cross-fertilization
(contained both clone genotypes; Figure 2– panel J). Transmission
of the resistant clone after drug treatment occasionally occurred at
lower gametocyte densities than was observed for sensitive clone
transmission, but also sometimes failed at densities greater than
10
3.5 per micro-liter mouse blood (Figure 5). Interestingly, the two
oocysts with clone S alleles that established from drug-treated mice
did so when densities of sensitive gametocytes in the blood were
lower than apparently necessary for transmission in the absence of
drug treatment (Figure 5).
The relationship between gametocyte density and probability of
mosquito infection is steeper in untreated mixed infections with
clone S transmission than drug-treated infections with clone R
transmission (Figure 5; clone: x
2(1, N=45)=195, p,0.001, clone x
gametocyte density: x
2(1, N=45)=163, p,0.001). The flatter slope of
the latter can be partly explained by three time points from three
different mice (feeds from one mouse on day 16 and two mice on
day 18) when R gametocyte densities over the transmission
threshold did not result in infections (Figure 5). However,
removing these three data points still revealed a significant slope
difference (clone x gametocyte density: x
2(1, N=42)=87, p,0.001).
The gametocyte density-infectivity relation is given by
q~ eazbN
1zeazbN ð2Þ
where q is the probability a mosquito becomes infected, N is the
log10 gametocyte density and parameters a=26.37 (61.28 SE)
and b=1.42 (60.37 SE) for clone R and a=212.69 (63.03 SE)
and b=3.60 (60.90 SE) for clone S. These infectivity functions
have a higher threshold density than those for P. falciparum
(Figure 5, [34,66,67]). The parameterized density-infection
function can be used to estimate infection thresholds. For example,
if we consider a minimum infection probability of 5%, then we
predict that clone R will require densities in the range of 10
1.2 to
10
3.7 gametocytes per ml of blood, and a range of 10
2.2–10
3.2 for
clone S to transmit the infection.
Discussion
As observed in previous studies [28,33,34], we found that
removal of drug-sensitive parasites by drug treatment led to
profound expansion the population of resistant parasites. We now
show experimentally that this release dramatically affects trans-
mission to mosquitoes, as was assumed in those earlier studies. In
sham-treated mice, resistant parasites were suppressed to such an
extent that transmissible gametocytes were undetectable in
peripheral mouse blood from day 10 post-infection, and in the
blood-meals of mosquitoes subsequently fed on these mice.
Moreover, resistant parasites did not contribute to any oocysts
generated by those infections. In contrast, the clearance of
sensitive parasites by chemotherapy led to resistant gametocyte
densities rising from barely detectable to approximately 90% of
transmissible parasites 48 hours after the cessation of treatment
(Figure 3A). Consequently, nearly all of the parasites (sporozoites)
Figure 4. Relationship between clone R gametocyte densities in mice at the time of a blood feed and in mosquito blood-meals fed
on those mice.
doi:10.1371/journal.pone.0037172.g004
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resistant genotype (Figure 2, panels G, H, I, J, K, L).
The density of resistant parasites within the gametocyte
population in mouse blood correlated closely with densities
recorded in mosquito blood-meals (Figure 4). This indicates that
counts obtained from tail-snip venous blood are an accurate
representation of those acquired by the mosquito: there is no
evidence that any gametocytes clumping in host capillaries resulted
in a difference in the genetic composition of the gametocyte
populations taken up by individual mosquitoes.
The gametocyte density-infectivity relation curves (Figure 5)
differed between clones, with a steeper increase in infectivity per
gametocyte density for clone S (Figure 5). This difference could be
due to a genetic difference between the clones, which may or may
not be related to resistance per se. Alternatively, the shallower slope
could be a result of drug treatment (the clone R data are all from
treated mice, and the clone S from untreated mice), or it might
reflect differences in the infectivity of gametocytes originating from
primary (clone R) or secondary (clone S) parasite peaks.
Experiments analogous to those performed here could be used
to investigate further the impact of parasite genetics, drug
treatment and immunity on these dose-response curves.
Gametocyte density-infectivity relationships are expected to be
s-shaped, with a density threshold below which negligible
transmission can occur, an initially accelerating curve as the
probability of gametes of both sexes finding each other in a
mosquito blood meal increases, then an approximately linear
phase during which an increasing number of gametocytes
increases the likelihood of establishing an infection within the
mosquito, and then finally saturation at some upper-bound
prevalence. This prevalence at saturation can be lower than
100% if, for example, there are refractory mosquitoes in the
population (e.g. [67]). Extrapolating from the model fitted to our
P. chabaudi data, saturation is expected to occur at densities over
10
4 gametocytes/ml, densities that are rarely attained in this host-
parasite system.
The WHO recommends that once more than 10% of patients
are failing to respond to treatment with a particular drug, that
drug be withdrawn from front-line use by national authorities [4].
One way to prevent the spread of parasites with resistance levels
high enough to render a drug insufficiently efficacious for clinical
use is to preemptively kill sensitive or semi-resistant parasites with
drugs, since dead parasites cannot mutate to the drug-threatening
high-level resistance. This is the resistance management justifica-
tion for designing treatment regimens aimed at removing all
parasites as fast as possible from a patient [4]. This strategy can be
an important weapon in the fight against drug resistance, but our
data clearly demonstrate the unavoidable downside of this strategy
[42]: it confers exceedingly strong evolutionary advantages on any
high-level resistance that is already present in an infection. The
resistant clone used in this experiment has previously been shown
to be unaffected by the doses of pyrimethamine used here [33–35]
and so it has the high-level resistance that resistance management
strategies are trying to prevent from spreading. In our experi-
ments, co-infection with the sensitive clone prevented the resistant
clone from transmitting to mosquitoes. Chemotherapy eliminated
Figure 5. Relationship between gametocyte densities in mice at the time of a blood feed and the subsequent prevalence of
infection in mosquitoes fed on those mice for untreated infections with transmission of clone S (red points) and for drug-treated
infections with transmission of clone R (black points). The thick red and black lines show the predicted probability of mosquito infection
based on logistic regression (eq 1), and the shaded areas show the 90% prediction intervals (note that these are not confidence intervals, see text for
details). Two oocysts consisting of clone S were observed in drug treated infections (open red triangles), these were not included in the model (see
text). Blue lines are gametocyte density-infectivity functions (of the form q=aN
b/[1+ cN
b]) estimated from P. falciparum data compiled by Carter and
Graves [66] and Barnes & White [67]: q1 (dot-dashed blue line;a=0.03, b=0.6, a/c=0.85) and q2 (solid blue line; a=1?1025, b=2, a/c=1) as
presented by Huijben et al. [34].
doi:10.1371/journal.pone.0037172.g005
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to the resistant parasites. Clearly, mice are not men (as discussed in
this context by Wargo et al. [33]), but it seems plausible that
competitive suppression will also occur in human infections. If so,
the process of competitive release will be a major determinant of
the rate of spread of high-level resistance in a population [38].
Note that it affects both the probability a patient will transmit
resistant parasites acquired from others as well as the probability
that any de novo mutations to high level resistance are able to reach
transmissible frequencies and escape from a patient in the first
place. Such processes may occur not only following therapeutic
drug use, but also following prophylactic chemotherapy such as
intermittent preventative therapy (IPT) in pregnant women,
infants or children [25,42] and will likely be dependent on the
ecological factors such as frequencies at the time of treatment and
the presence of other clones at the time of infection [30,35,57].
Thus, chemotherapy is a double-edged sword for resistance
management [42]. It can, by killing parasites, control the
probability that de novo mutants will occur in a patient in the first
place, but only at the cost of imposing very strong selection for any
that are already there. Chemotherapeutic regimens designed to
remove all parasites as fast as possible can confer substantial
benefits (e.g. clinical gains, or minimizing the number of parasites
which are alive to mutate), but they will have the highly
undesirable consequence of maximally spreading any high-level
resistant parasite that is present. A better understanding of clone-
clone interactions, and of the effect of different drugs and
treatment regimens on those interactions, may help identify new
ways to improve patient health while limiting the transmission
advantages chemotherapy confers on resistance parasites. Mean-
while, treated patients should be urged to use bednets in the period
after treatment to reduce the chances they will spread resistant
parasites to others.
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